BioCentury Podcasts

•

Canal • 2 programas

Ciencias de la vida

Ciencias de la vida

Cada semana
Ciencias de la vida

Ciencias de la vida

Cada dos semanas

HACE 3 DÍAS

Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch

2025 marked the end of a four-year slide in series A financings for biotechs, with 144 biotechs raising an aggregate of $8 billion, up $1 billion from the prior two years. On the latest BioCentury This Week podcast, BioCentury’s Danielle Golovin assesses which companies VCs backed last year and what their investments say about where technology is headed. Washington Editor Steve Usdin offers a perspective on why compounded Wegovy is an assault on the biopharma industry and also explains how the spending bill signed into law last week is a rebuke to proposed White House biomedical cuts. And Executive Editor Selina Koch unpacks her interview on The BioCentury Show podcast with neuroscientist and Seaport Chair Steven Paul, noting that while serendipity drives drug discovery in psychiatry, it’s engineering that gets it across the finish line. View full story: https://www.biocentury.com/article/658367 #BiotechFinancing #SeriesAFunding #VentureCapital #DrugDiscovery #BiopharmaPolicy 00:00 - Introduction 02:15 - Start-up Spotlight 11:03 - Compounded Wegovy 18:10 - Congress Rebuffs Trump Cuts 23:50 - Steve Paul on Neuropsychiatry To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

hace 3 días

•

34 min
3 FEB

Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

RNAi and exon-skipping therapies headline the list of regulatory and pivotal data catalysts in 2026, while new lipid-lowering mechanisms, modalities, and precision medicines define cardiovascular disease catalysts this year. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the most important milestones of the year in new modalities, CV and renal diseases. The analysts also discuss a new regulation in China introducing orphan drug exclusivity that could incentivize development of rare disease therapies. Dig into the BioCentury’s catalyst picks and the new China policy below • 2026 Catalysts: The rise of RNAi • 2026 Cardiovascular Catalysts: Lp(a) on the Horizon • 2026 Obesity Catalysts: Launches, readouts and challengers • 2026 Catalysts: Breakthrough progress in renal disease • AZ signals all-in on obesity via CSPC deal for $1.2B up front • China’s orphan drug exclusivity could bolster market, incentivize development View full story: https://www.biocentury.com/article/658286 00:00 - Introduction 02:28 - RNAi and Antisense Therapies 06:37 - Neuromuscular and Musculoskeletal 10:33 - Renal Disease Catalysts 22:26 - China's New Orphan Rules To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

3 feb

•

31 min
27 ENE

Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos

New rules in China will accelerate the country’s cell and gene therapy sector by reshaping how investigator-initiated trials are conducted and commercialized. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the new framework and why it will create a powerful incentive for deploying new gene and cell therapies. Executive Editor Selina Koch discusses which milestones she is watching in neurology in the year ahead, from psychedelics to Alzheimer's disease. Finally, Senior Biopharma Analyst Danielle Golovin discusses a pair of stories from BioCentury’s Emerging Company Profile series: one focused on Yale spinout Bexorg Inc., which is rethinking CNS drug discovery with a whole-human-brain model, and another on Elkedonia S.A.S., a French start-up aiming at ELK1 to reboot neuroplasticity in depression. View full story: https://www.biocentury.com/article/658189 00:00 - Introduction 03:14 - Speeding China's Innovation 10:36 - Neuro Catalysts 22:01 - Newcos To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

27 ene

•

30 min
01/07/2025

Ep. 305 - FDA's Future; In Vivo CAR T Plays; Psychedelics; CDK2

The Trump administration’s overhaul of FDA is still underway, but the agency has already veered away from its decades-long trajectory in ways that will profoundly reshape medical product development and the lives of U.S. patients. On the latest BioCentury This Week podcast, BioCentury’s analysts assess who the winners and losers are likely to be as FDA changes shape. The analysts discuss a pair of in vivo CAR T companies: Esobiotec, whose story offers a case study in product-focused strategy, and Capstan Therapeutics, whose in vivo CAR T platform for immunological disorders attracted a buyer in Abbvie. The team also analyzes why data from Compass Pathways for psilocybin therapy COMP360 disappointed investors despite hitting the endpoint, and how molecular glues could be the future of selective CDK2 targeting. This episode of BioCentury This Week was sponsored by ICON Biotech. View full story: https://www.biocentury.com/article/656341 #biotech #biopharma #pharma #lifescience #RandD #drugapproval 00:01 - Sponsor Message: ICON Biotech 02:26 - BioCentury Grand Rounds Europe 05:02 - FDA's Future 15:03 - Psychedelics 22:53 - Esobiotech's Fast Exit 31:37 - Molecular Glues and CDK2 34:43 - Abbvie's Capstan Buy To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

01/07/2025

•

39 min
27/08/2024

Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update

Shaking up an underwhelming year for fresh biotech paper, a trio of biotechs filed to go public on NASDAQ last week. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the IPO filings by MBX and Massachusetts companies Zenas and Bicara. Washington Editor Steve Usdin returns to the podcast to provide updates on the Inflation Reduction and Biosecure acts, as well as the life sciences policies of presidential candidates Donald Trump and Kamala Harris. And Director of Biopharma Intelligence Karen Tkach Tuzman zeroes in on the latest trends among pharma’s deals with biotechs over the past 12 months and the latest start-up out of Versant Ventures, Borealis. View full story: https://www.biocentury.com/article/653354 00:00 - Introduction 01:48 - Biotech IPOs 12:48 - Washington Update 20:39 - Versant, Novartis Newco 24:34 - Pharma-Biotech Deal Trends Reach us by sending a text

27/08/2024

•

29 min
13 ENE

Ep. 343 - JPM Deals, Policy Outlook, Approval Trends

Riding the tailwind of a strong 2H25, the days leading up to biotech’s annual kickoff meeting in San Francisco delivered billions in capital raised and more than two dozen deals announced. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss two of the largest deals announced at the start of the J.P. Morgan Healthcare Conference, a partnership for a bispecific between AbbVie and RemeGen and the launch of “NewCo” AirNexus Therapeutics by Haisco Pharmaceutical and a syndicate led by Frazier Life Sciences. The analysts also discuss Washington Editor Steve Usdin’s policy outlook for the year ahead, and Executive Director of Biopharma Intelligence Lauren Martz’s analysis of trends in FDA’s 2025 approvals. View full story: https://www.biocentury.com/article/658052 #JPMHealthcare #BiotechFinancing #BiopharmaPartnerships #FDAApprovals #BiotechPolicy 00:00 - Introduction 01:55 - JPM Deals 11:49 - Policy Outlook 19:30 - Trends in Drug Approvals To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

13 ene

•

25 min
17/09/2024

Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech

On the latest BioCentury This Week podcast, BioCentury’s editors assess the shifting market for biotech IPOs, including the profiles of the three companies that went public on NASDAQ last week, the aftermarket performance of the year's IPO class, and the prospects for more companies to make their own debut in the coming months. BioCentury’s editors also discuss whether the rush to GLP-1s for obesity will mirror the development of PD-1s for cancer and the impact on biopharma of the recent mainstream expansion of AI. This episode of BioCentury This Week was sponsored by Parexel Biotech. View full story: https://www.biocentury.com/article/653538 00:01 - Sponsor Message: Parexel Biotech 01:30 - IPOs 10:56 - GLP-1 & Obesity 22:18 - AI & Biotech To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

17/09/2024

•

33 min
6 ENE

Ep. 342 - 2026 Biotech Kickoff

The New Year begins with biotech running along parallel storylines. There’s cause for optimism as the industry’s financing gears have begun to churn again and innovation remains as strong as it has ever been, while there's cause for concern as the world’s most stable, progressive, science-based regulatory system has become unpredictable amid new leadership at HHS, FDA, and NIH. On the first episode of the BioCentury This Week podcast’s seventh year, BioCentury’s analysts assess the state of play for biotech in the U.S., Europe, and Asia. The discussion ranges from recent changes at NIH to what’s next for rare pediatric disease priority review vouchers, and from Europe’s opportunity as FDA enters uncertain terrain to Japan’s evolving biotech landscape. Early bird rates for BioCentury and BayHelix’s fifth East-West Biopharma Summit end Friday. Act now to join investors, dealmakers and innovators in Seoul this March to source innovation from Asia, or accelerate your own pipeline by finding the right Asia partner. View full story: https://www.biocentury.com/article/657978 #BiotechOutlook #FDAUncertainty #GlobalBiotech #RarePediatricDiseasePRV #NIHLeadership 00:00 - Introduction 01:46 - 2026 Outlook 03:56 - Policy Landscape 11:48 - Priority Review Vouchers 15:03 - Global Perspectives 16:57 - Spotlight on Japan 21:55 - European Biotech Opportunities To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

6 ene

•

26 min
17/01/2025

Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds

Sunshine and a stream of deals brightened the mood at this year’s J.P. Morgan Healthcare Conference, offering a pleasant counterpoint to continued pessimism over the state of the capital markets. On the latest BioCentury This Week podcast, BioCentury’s editors deliver their takeaways from biotech’s annual kick-off event from megarounds and Asian newcos to the new state of M&A and pending change at FDA. View full story: https://www.biocentury.com/article/654723 00:00 - Introduction 01:52 - Market Sentiments and Deal Expectations 04:42 - Cross-Border Deals and Asia's Growing Influence 07:12 - Neurology and Innovation in Biotech 14:44 - VC Trends and Megarounds 20:00 - Upcoming East West Singapore To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

17/01/2025

•

22 min
30/12/2024

Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data

Preview: In his five decades at FDA, Robert “Bob” Temple helped revolutionize the ways medical products are developed and regulated. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin reflects on the legacy of Temple. Temple, who is retiring, crafted the modern clinical trial paradigm, created the accelerated approval pathway, and set precedents for incorporating patient perspectives in regulatory decisions. Usdin also discusses the opportunities and threats for the agency under Trump 2.0.BioCentury's editors also discuss China’s academic innovation, arguing that a wave of new target biology is now coming from Chinese university labs and the underwhelming results from CagriSema’s latest readout. Phase III data for the most important weight loss candidate from Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) failed to differentiate the product from Eli Lilly's Zepbound. View full story:https://www.biocentury.com/article/654574/temple-s-fda-legacy-plus-chinese-innovation-novo-obesity-data-a-biocentury-podcast 00:00 - Introduction 02:03 - Bob Temple's Legacy 16:13 - China's Academic Innovation 26:20 - CagriSema Obesity Data To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

30/12/2024

•

35 min

BioCentury Podcasts leverage three decades of biopharma intelligence with thoughtful, accurate, and objective insights. BioCentury editors spotlight key scientific opinion leaders, corporate decision-makers, venture capitalists, and patient advocates, keeping you informed on the most current biotech stories and highlighting life science innovations.

Sitio web

BioCentury Podcasts

Top programas

Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch

Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos

Ep. 305 - FDA's Future; In Vivo CAR T Plays; Psychedelics; CDK2

Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update

Ep. 343 - JPM Deals, Policy Outlook, Approval Trends

Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech

Ep. 342 - 2026 Biotech Kickoff

Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds

Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data

Acerca de

BioCentury Podcasts

Top programas

Top episodios

Acerca de